In a dynamic and fast-changing market environment, a nuanced understanding of pricing and market access is increasingly important for pharmaceutical and biotech companies to succeed commercially. Reimbursement, coding, and the influence of public policy on pricing and access are becoming more complex, requiring careful evaluation and evidence-based solutions.
Comprehensive Solutions for All
Pricing and market access should not only be a priority for big pharma companies and blockbuster drugs; rather, it must be taken into consideration for organizations and product launches of all sizes. Too often, pricing and access strategies are not developed until a product is nearly launched, leaving insufficient time to determine the pathway to optimal revenue, coverage, and uptake.
Strategic Expertise and Integrated Support
Drawing from years of strategic and practical experience, EMC supports our clients in navigating this area of commercial strategy that is perhaps the greatest potential pitfall – or accelerator – to success for new and on-market life sciences products. Unlike other consultancies, EMC can coordinate with the broader EVERSANA network of service providers – such as HEOR experts, field teams, and patient HUBs – to provide comprehensive insights into any and all pricing and access needs.
Our Comprehensive Pricing & Market Access Consulting Services
- Market Access Landscape Assessment
- Market Opportunity Assessment and Commercial Forecast
- Access Launch Strategy and Tactical Execution Planning
- Indication Prioritization
- Reimbursement Focused Clinical Trial Design
- Early Asset Pricing
- Value Proposition Development and Validation
- Pricing and Contracting Strategy
- Coding and reimbursement strategy, including coding applications
- Channel and Distribution strategy
- Account segmentation and prioritization
- Payer opinion leader mapping
- Indication prioritization and launch sequencing
- Scenario planning and competitive gaming
